Suppr超能文献

鉴定潜在的含 GluN2B 亚基的 N-甲基-D-天冬氨酸受体抑制剂:一种综合和分子建模方法。

Identifying potential GluN2B subunit containing N-Methyl-D-aspartate receptor inhibitors: an integrative and molecular modeling approach.

机构信息

Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi, India.

Poona College of Pharmacy, Bharti Vidyapeeth University, Pune, India.

出版信息

J Biomol Struct Dyn. 2020 Jun;38(9):2533-2545. doi: 10.1080/07391102.2019.1635530. Epub 2019 Jul 4.

Abstract

N-methyl-D-aspartate receptors (NMDARs), a class of ligand-gated ion channels, are involved in non-selective cation transport across the membrane. These are contained in glutamatergic synapse and produce excitatory effects leading to synaptic plasticity and memory function. GluN1-GluN2B, a subtype of NMDAR(s), has significant role in neurodegeneration, amyloid β (Aβ) induced synaptic dysfunction and loss. Thus, targeting and inhibiting GluN1-GluN2B may be effective in the management of neurodegenerative diseases including Alzheimer's disease. In the present study, ligand and structure-based approaches were tried to identify the inhibitors. The pharmacophore, developed from co-crystallised ifenprodil, afforded virtual hits, which were further subjected through drug likeliness and PAINS filters to remove interfering compounds. Further comprehensive docking studies, free energy calculations and ADMET studies resulted in two virtual leads. The leads, ZINC257261614 and ZINC95977857 displayed good docking scores of -12.90 and -12.20 Kcal/mol and free binding energies of -60.83 and -61.83 Kcal/mol, respectively. The compounds were having acceptable predicted ADMET profiles and were subjected to molecular dynamic (MD) studies. The MD simulation produced stable complexes of these ligands with GluN1-GluN2B subunit having protein and ligand RMSD in acceptable limit. AbbreviationsADAlzheimer's diseaseADMEAbsorption distribution metabolism and excretionATDAmino terminal domainBBBBlood-brain barrierCNSCentral nervous systemCREBcAMP response element binding proteinCTDCarboxy-terminal domainGluGlutamateGMQEGlobal model quality estimationHTVSHigh throughput virtual screeningHIAHuman intestinal absorptionLGALamarckian genetic algorithmMDMolecular dynamicsMM-GBSAMolecular mechanics, the Generalised Born model for Solvent AccessibilityNMDARN-methyl-D-aspartate receptorsPAINSPan assay interference compoundsRMSDRoot-mean square deviationRMSFRoot-mean-square fluctuationSMARTSSMILES arbitrary target specificationSPstandard precisionXPextra precisionCommunicated by Ramaswamy H. Sarma.

摘要

N-甲基-D-天冬氨酸受体(NMDARs)是一类配体门控离子通道,参与跨膜的非选择性阳离子转运。这些受体存在于谷氨酸能突触中,产生兴奋作用,导致突触可塑性和记忆功能。GluN1-GluN2B 是 NMDAR 的一种亚型,在神经退行性变、淀粉样β(Aβ)诱导的突触功能障碍和丧失中起重要作用。因此,针对和抑制 GluN1-GluN2B 可能对包括阿尔茨海默病在内的神经退行性疾病的治疗有效。在本研究中,尝试了基于配体和结构的方法来鉴定抑制剂。从共结晶的ifenprodil 中开发的药效基团产生了虚拟命中,进一步通过药物相似性和 PAINS 过滤器进行筛选,以去除干扰化合物。进一步的综合对接研究、自由能计算和 ADMET 研究得到了两个虚拟先导化合物。先导化合物 ZINC257261614 和 ZINC95977857 的 docking 得分分别为-12.90 和-12.20 Kcal/mol,自由结合能分别为-60.83 和-61.83 Kcal/mol。这些化合物具有可接受的预测 ADMET 特征,并进行了分子动力学(MD)研究。MD 模拟产生了这些配体与 GluN1-GluN2B 亚基的稳定复合物,其蛋白和配体 RMSD 在可接受的范围内。缩写AD阿尔茨海默病ADME吸收、分布、代谢和排泄ATDA 氨基末端结构域BBBB 血脑屏障CNS中枢神经系统CREBcAMP 反应元件结合蛋白CTD 羧基末端结构域Glu 谷氨酸GMQE 全局模型质量估计HTVS 高通量虚拟筛选HIA 人肠道吸收LGALamarckian 遗传算法MD 分子动力学MM-GBSA 分子力学,溶剂可及性的广义 Born 模型NMDAR N-甲基-D-天冬氨酸受体PAINS 泛assay 干扰化合物RMSD 均方根偏差RMSF 均方根波动SMARTS SMILES 任意靶规格SP 标准精度XP 额外精度由 Ramaswamy H. Sarma 传达。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验